Search results
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 1 day agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 22 hours agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 5 days agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 4 days agoOne of the drugs, the lung cancer treatment Tagrisso, has already exceeded $5 billion in annual...
Why This Top 4% Biotech Just Catapulted To A Record High
Investor's Business Daily· 21 hours agoThe Netherlands-based biotech paired its drug, petosemtamab, with Merck's (MRK) cancer blockbuster, ...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 2 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Immunotherapy for stomach cancer: Types and effectiveness
Medical News Today· 3 days agoImmunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in...
Merus Shares Surge 36% On Early Data of Potential Head, Neck Cancer Treatment
Market Watch· 1 day agoShares of Merus surged higher Friday after the company's head and neck cancer treatment candidate showed a reduction in the disease in 60% of evaluable patients in an early ...
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Zacks· 2 days agoFree Report) announced updated clinical results from a cohort of the phase II IOV-COM-202 study evaluating the combination of its recently approved cell therapy Amtagvi and Merck’s blockbuster ...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 1 day agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...